Document detail
ID
doi:10.1038/s41698-024-00598-7...
Author
Li, Zi-Jing Pat Fong, William Zhang, Dong-Sheng Luo, Hui-Yan Chen, Dong-Liang Cai, Yan-Yu Chen, Zhi-Gang Duan, Jian-Li Huang, Zi-Yao Lu, Yu-Ting Huang, Xiao-Xia Li, Yu-Hong Wang, De-ShenLangue
enEditor
Nature
Category
Medicine & Public Health
Year
2024
listing date
5/15/2024
Keywords
cancer alki alk crcAbstract
Anaplastic lymphoma kinase (ALK) fusion-positive colorectal cancer (CRC) is a rare and chemotherapy-refractory subtype that lacks established and effective treatment strategies.
Additionally, the efficacy and safety of ALK inhibitors (ALKi) in CRC remain undetermined.
Herein, we examined a series of ALK-positive CRC patients who underwent various lines of ALKi treatment.
Notably, we detected an ALK 1196M resistance mutation in a CRC patient who received multiple lines of chemotherapy and ALKi treatment.
Importantly, we found that Brigatinib and Lorlatinib demonstrated some efficacy in managing this patient, although the observed effectiveness was not as pronounced as in non-small cell lung cancer cases.
Furthermore, based on our preliminary analyses, we surmise that ALK-positive CRC patients are likely to exhibit inner resistance to Cetuximab.
Taken together, our findings have important implications for the treatment of ALK-positive CRC patients.
Li, Zi-Jing,Pat Fong, William,Zhang, Dong-Sheng,Luo, Hui-Yan,Chen, Dong-Liang,Cai, Yan-Yu,Chen, Zhi-Gang,Duan, Jian-Li,Huang, Zi-Yao,Lu, Yu-Ting,Huang, Xiao-Xia,Li, Yu-Hong,Wang, De-Shen, 2024, Exploring ALK fusion in colorectal cancer: a case series and comprehensive analysis, Nature
Evaluating Image Hallucination in Text-to-Image Generation with Question-Answering
evaluation computer dataset images tti generation i-halla
Role of Repetitive Transcranial Magnetic Stimulation in Treatment of Fibromyalgia: A Randomized Controlled Trial
significant following stimulation fms treatment
